28584284|t|Erythropoietin ameliorates diabetes-associated cognitive dysfunction in vitro and in vivo.
28584284|a|Several studies indicate that erythropoietin (EPO) has remarkable neuroprotective effects in various central nervous system disorders, while little is known about the effects of EPO in diabetes-associated cognitive dysfunction. Therefore, the present study aimed to investigate whether EPO ameliorates diabetes-associated cognitive dysfunction in vivo and in vitro. We investigated the protective effects of EPO on high-glucose (HG)-induced PC12 cell death and oxidative stress. The effects of EPO (300 U/kg administered three times a week for 4 weeks) on diabetes-associated cognitive decline were investigated in diabetic rats. EPO significantly increased cell viability, increased the activity of superoxide dismutase, decreased the production of malondialdehyde and reactive oxygen species, and decreased the apoptosis rate. Additionally, LY294002, a phosphatidylinositol 3-kinase (PI3K) inhibitor, abolished the protective effects of EPO in HG-treated PC12 cells. In diabetic rats, EPO prevented deficits in spatial learning and memory in the Morris water maze test. The results of real-time PCR and Western blotting showed that EPO upregulated EPO receptor, PI3K, and phosphorylated Akt2 relative to unphosphorylated Akt2 (p-Akt2/Akt2) and downregulated glycogen synthase kinase-3beta (GSK-3beta). These studies demonstrate that EPO is an effective neuroprotective agent in the context of diabetes-associated cognitive dysfunction and show that this effect involves the PI3K/Akt/GSK-3beta pathway.
28584284	0	14	Erythropoietin	Gene	24335
28584284	27	35	diabetes	Disease	MESH:D003920
28584284	47	68	cognitive dysfunction	Disease	MESH:D003072
28584284	121	135	erythropoietin	Gene	24335
28584284	137	140	EPO	Gene	24335
28584284	192	224	central nervous system disorders	Disease	MESH:D002493
28584284	269	272	EPO	Gene	24335
28584284	276	284	diabetes	Disease	MESH:D003920
28584284	296	317	cognitive dysfunction	Disease	MESH:D003072
28584284	377	380	EPO	Gene	24335
28584284	393	401	diabetes	Disease	MESH:D003920
28584284	413	434	cognitive dysfunction	Disease	MESH:D003072
28584284	499	502	EPO	Gene	24335
28584284	506	518	high-glucose	Chemical	-
28584284	520	522	HG	Chemical	-
28584284	532	536	PC12	CellLine	CVCL:0481
28584284	585	588	EPO	Gene	24335
28584284	647	655	diabetes	Disease	MESH:D003920
28584284	667	684	cognitive decline	Disease	MESH:D003072
28584284	706	714	diabetic	Disease	MESH:D003920
28584284	715	719	rats	Species	10116
28584284	721	724	EPO	Gene	24335
28584284	841	856	malondialdehyde	Chemical	MESH:D008315
28584284	861	884	reactive oxygen species	Chemical	MESH:D017382
28584284	934	942	LY294002	Chemical	MESH:C085911
28584284	946	975	phosphatidylinositol 3-kinase	Gene	85243
28584284	1030	1033	EPO	Gene	24335
28584284	1037	1039	HG	Chemical	-
28584284	1048	1052	PC12	CellLine	CVCL:0481
28584284	1063	1071	diabetic	Disease	MESH:D003920
28584284	1072	1076	rats	Species	10116
28584284	1078	1081	EPO	Gene	24335
28584284	1225	1228	EPO	Gene	24335
28584284	1280	1284	Akt2	Gene	25233
28584284	1314	1318	Akt2	Gene	25233
28584284	1322	1326	Akt2	Gene	25233
28584284	1327	1331	Akt2	Gene	25233
28584284	1351	1381	glycogen synthase kinase-3beta	Gene	84027
28584284	1383	1392	GSK-3beta	Gene	84027
28584284	1426	1429	EPO	Gene	24335
28584284	1486	1494	diabetes	Disease	MESH:D003920
28584284	1506	1527	cognitive dysfunction	Disease	MESH:D003072
28584284	1572	1575	Akt	Gene	24185
28584284	1576	1585	GSK-3beta	Gene	84027
28584284	Negative_Correlation	MESH:D017382	24335
28584284	Positive_Correlation	24335	25233
28584284	Association	24185	24335
28584284	Association	MESH:C085911	24335
28584284	Negative_Correlation	24335	84027
28584284	Negative_Correlation	MESH:D003072	24335
28584284	Negative_Correlation	MESH:D008315	24335
28584284	Association	MESH:D003072	24185
28584284	Association	24335	85243
28584284	Association	MESH:D003072	84027
28584284	Negative_Correlation	MESH:C085911	85243
28584284	Association	MESH:D003920	24335

